Pacific Edge seeks $35.3M to fund US growth

Pacific Edge, the listed cancer diagnostics company, is planning a $35.3 million renounceable rights offer at a 6.2 per cent discount to fund its US growth strategy, potentially launch into Singapore as a gateway to South East Asia,…